Merck CEO Says Company Will Raise Its $70 Billion Mid-2030s Revenue Target

Rob Davis pointed to an acquisition, a PD-1/VEGF drug and a stronger cancer vaccine profile that the original $70 billion figure missed.

Share
Merck CEO Says Company Will Raise Its $70 Billion Mid-2030s Revenue Target

Merck expects to raise its $70 billion revenue opportunity for the mid-2030s, Chairman and CEO Rob Davis told analysts on the company's third-quarter earnings call Thursday. Merck, which makes prescription medicines, vaccines and animal health products, said pipeline wins and assets the first figure left out or undervalued justify a bigger number.

Three reasons the number was too low

Asked by a Goldman Sachs analyst how the $70 billion framing has changed, Davis said clinical data so far give him "increased confidence" in it. "We expect now to be raising that number," he said.

He named what the original figure left out. The acquisition he called "the turns acquisition" was not included, and Davis said it "is going to be addition to that number." Merck also "put nothing in for the PD-1 VEGF," he said, and its confidence in that drug as a combination agent with sac-TMT is growing after data at several conferences.

The cancer vaccine intismeran autogene, which Merck is developing with Moderna, was in the original expectation. But Davis said the data point to a better commercial profile, so "the targeted product profile now is stronger." He added that sac-TMT is likely to reach broader indications as new studies start.

Davis cautioned that "every card's a new card" until data arrive, and said more catalysts are coming over the next 12 to 24 months.

The Keytruda cliff behind the target

The target matters because Keytruda, Merck's top-selling cancer drug, faces generic competition when its key patents begin expiring in 2028. Davis said he feels good about Merck's ability to navigate that loss of exclusivity.

CFO Caroline Litchfield said 2027 carries more than $2 billion of headwinds from generic competition on Bridion, the Januvia family and Adempus. She also expects only modest revenue growth that year, and called the Keytruda patent expiry "more of a hill" on revenue before a return to strong growth.

Third-quarter revenue was $18.1 billion, up 5%, or 4% excluding currency. Keytruda family sales rose 6% to $8.6 billion. Merck narrowed its 2026 revenue guidance to $66.8 billion to $67.3 billion and raised the midpoint.

Milestones ahead for sac-TMT

Dr. Dean Li, president of Merck Research Laboratories, listed potential approval of sac-TMT in endometrial cancer among milestones expected over the next 12 months, along with a filing for intismeran. Merck also plans phase three studies of sac-TMT with its PD-1/VEGF drug in first-line lung cancer in the first half of 2027.

Merck shares were up 4.71% to $147.57 in Thursday trading, as of 10:33 a.m. ET.

Davis did not put a new figure on the target on the call; the company's next catalysts, he said, arrive over the next 12 to 24 months.

Sources

More on Merck

All Merck (MRK) coverage →